RPS5 and colorectal cancer: Furthermore, using HCT-15 human colorectal cancer cells harboring p53 mutation, we observed that sub-G1 population did not increase when RPS5-depleted HCT-15 cells were treated with trametinib (Supplementary Material Appendix, Figure S2A and B).